Anti-CERU/ CP/ CP-2 monoclonal antibody
Anti-CERU/ CP/ CP-2 antibody for FACS & in-vivo assay
Go to CP/CP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0329-Ab-1/ GM-Tg-hg-MP0329-Ab-2 | Anti-Human CP monoclonal antibody | Human |
GM-Tg-rg-MP0329-Ab-1/ GM-Tg-rg-MP0329-Ab-2 | Anti-Rat CP monoclonal antibody | Rat |
GM-Tg-mg-MP0329-Ab-1/ GM-Tg-mg-MP0329-Ab-2 | Anti-Mouse CP monoclonal antibody | Mouse |
GM-Tg-cynog-MP0329-Ab-1/ GM-Tg-cynog-MP0329-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CP monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0329-Ab-1/ GM-Tg-felg-MP0329-Ab-2 | Anti-Feline CP monoclonal antibody | Feline |
GM-Tg-cang-MP0329-Ab-1/ GM-Tg-cang-MP0329-Ab-2 | Anti-Canine CP monoclonal antibody | Canine |
GM-Tg-bovg-MP0329-Ab-1/ GM-Tg-bovg-MP0329-Ab-2 | Anti-Bovine CP monoclonal antibody | Bovine |
GM-Tg-equg-MP0329-Ab-1/ GM-Tg-equg-MP0329-Ab-2 | Anti-Equine CP monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0329-Ab-1/ GM-Tg-hg-MP0329-Ab-2; GM-Tg-rg-MP0329-Ab-1/ GM-Tg-rg-MP0329-Ab-2; GM-Tg-mg-MP0329-Ab-1/ GM-Tg-mg-MP0329-Ab-2; GM-Tg-cynog-MP0329-Ab-1/ GM-Tg-cynog-MP0329-Ab-2; GM-Tg-felg-MP0329-Ab-1/ GM-Tg-felg-MP0329-Ab-2; GM-Tg-cang-MP0329-Ab-1/ GM-Tg-cang-MP0329-Ab-2; GM-Tg-bovg-MP0329-Ab-1/ GM-Tg-bovg-MP0329-Ab-2; GM-Tg-equg-MP0329-Ab-1/ GM-Tg-equg-MP0329-Ab-2 |
Products Name | Anti-CP monoclonal antibody |
Format | mab |
Target Name | CP |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CP benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CERU/ CP/ CP-2 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP0329 |
Target Name | CP |
Gene ID | 1356,12870,24268,712210,514194,100058573 |
Gene Symbol and Synonyms | AB073614,CERP,CP,CP-2,D3Ertd555e |
Uniprot Accession | P00450,P13635 |
Uniprot Entry Name | CERU_HUMAN,CERU_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | Prostate Cancer, Type 2 diabetes mellitus, Sepsis, Type 2 diabetes mellitus with diabetic nephropathy, Diabetic Nephropathy, IgA glomerulonephritis, laryngeal cancer, Lung cancer, Other diseases of intestines (K55-K64), Renal cell carcinoma |
Gene Ensembl | ENSG00000047457 |
Target Classification | N/A |
The target: CP, gene name: CP, also named as CP-2. The protein encoded by this gene is a metalloprotein that binds most of the copper in plasma and is involved in the peroxidation of Fe(II)transferrin to Fe(III) transferrin. Mutations in this gene cause aceruloplasminemia, which results in iron accumulation and tissue damage, and is associated with diabetes and neurologic abnormalities. Two transcript variants, one protein-coding and the other not protein-coding, have been found for this gene. [provided by RefSeq, Feb 2012].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.